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This is 1 of 5 articles generated from the SETAC Pellston Workshop “Ecotoxicological Hazard and Risk Assessment
Approaches for Endocrine-Active Substances (EHRA)” (February 2016, Pensacola, Florida, USA). The primary aim of the
workshop was to provide objective advice, based on current scientific understanding, to regulators and policy makers,
whether in industry, government, or academia. The goal is to make considered, informed decisions on whether to select an
ecotoxicological hazard- or risk-based approach for regulating a given endocrine disrupting substance under evaluation.teABSTRACT
A SETAC Pellston Workshop
1
“Environmental Hazard and Risk Assessment Approaches for Endocrine-Active Substances
(EHRA)” was held in February 2016 in Pensacola, Florida, USA. The primary objective of the workshop was to provide advice,
based on current scientific understanding, to regulators and policy makers; the aim being to make considered, informed
decisions on whether to select an ecotoxicological hazard- or a risk-based approach for regulating a given endocrine-
disrupting substance (EDS) under review. The workshop additionally considered recent developments in the identification of
EDS. Case studies were undertaken on 6 endocrine-active substances (EAS—not necessarily proven EDS, but substances
known to interact directly with the endocrine system) that are representative of a range of perturbations of the endocrine
system and considered to be data rich in relevant information at multiple biological levels of organization for 1 or more
ecologically relevant taxa. The substances selected were 17a-ethinylestradiol, perchlorate, propiconazole, 17b-trenbolone,
tributyltin, and vinclozolin. The 6 case studies were not comprehensive safety evaluations but provided foundations for
clarifying key issues and procedures that should be considered when assessing the ecotoxicological hazards and risks of EAS
and EDS. The workshop also highlighted areas of scientific uncertainty, and made specific recommendations for research and
methods-development to resolve some of the identified issues. The present paper provides broad guidance for scientists in
regulatory authorities, industry, and academia on issues likely to arise during the ecotoxicological hazard and risk assessment
of EAS and EDS. The primary conclusion of this paper, and of the SETAC PellstonWorkshop on which it is based, is that if data
on environmental exposure, effects on sensitive species and life-stages, delayed effects, and effects at low concentrations are
robust, initiating environmental risk assessment of EDS is scientifically sound and sufficiently reliable and protective of the
environment. In the absence of such data, assessment on the basis of hazard is scientifically justified until such time as relevant
new information is available. Integr Environ Assess Manag 2017;13:267–279. C 2017 The Authors. Integrated Environmental
Assessment and Management published by Wiley Periodicals, Inc. on behalf of Society of Environmental Toxicology &
Chemistry (SETAC)
Keywords: Endocrine disruptors Ecotoxicological hazard assessment Ecotoxicological risk assessmentINTRODUCTION AND BACKGROUND
The purpose of the present consensus paper is to provide
scientific information on current best practices in the
evaluation of hazards and risks to wildlife populations of
endocrine-active substances (EAS) and endocrine-disrupt-
ing substances (EDS), developed using a cross-section of
international expertise. There have been many descriptions
of environmental EDS and their effects, including those of
the World Health Organization and International Pro-
gramme on Chemical Safety (WHO/IPCS 2002) and the
WHO and United Nations Environment Programme (WHO/
UNEP 2012), and it is well established that some EDS are, orgr Environ Assess Manag 2017:267–279 wileyonlinelibrary.chave been, present in the environment at concentrations
harmful to wildlife populations (e.g., Jobling et al. 2006;
Matthiessen 2013).
Although other definitions have also been proposed (e.g.,
Kavlock et al. 1996; EC 1997; Zoeller et al. 2012; Weltje et al.
2013), the broad WHO definition of an EDS has been most
widely adopted, and is used herein:
“An endocrine disruptor is an exogenous substance or
mixture that alters function(s) of the endocrine system and
consequently causes adverse health effects in an intact
organism, or its progeny, or (sub) populations” [emphasis
added] (WHO/IPCS 2002).C 2017 The Authorsom/journal/ieam
Ecotoxicological Evaluation of Endocrine-Active Substances—Integr Environ Assess Manag 13, 2017 269In contrast to EDS (which generally can only be identified
by definitive dose–response studies), an EAS is any
substance able to interact with an endocrine system to
cause responses that may or may not give rise to adverse
effects (see Glossary for full definitions of terms used). An
EAS may therefore be identified using screening-level
information.
In response to concerns about the ecotoxicological effects
of EDS, individual countries and international governments
and organizations, including Japan, the United States of
America (USA), the European Union (EU), and the Organisa-
tion for Economic Co-operation and Development (OECD)
have, over the past 20 y, initiated programs for assessing
potential impacts of EAS to wildlife (as well as human health)
(Coady et al. this issue). In most jurisdictions, the goal of
regulation is to prevent adverse effects on wildlife popula-
tions rather than on individuals. This goal has led to many
discussions about how to conduct risk assessments of these
substances, or even whether this is appropriate (Zoeller et al.
2015; Coady et al. 2016). In other words, should some or all
EDS be treated as persistent organic pollutants (POPs);
persistent, bioaccumulative, and toxic (PBT) substances; or
genotoxic carcinogens, for which it is presumed a risk exists if
exposure, no matter how small, occurs?
Several jurisdictions have initiated regulatory approaches
to EDS, but these have varied, partly because until now there
has been little consensus about some key scientific questions.
For example, some scientists believe that EDS can be reliably
assessed using the standard risk assessment paradigm (i.e.,
comparison of predicted environmental concentrations with
predicted no-effect concentrations [PNECs]), whereas others
do not believe this is sufficiently precautionary and propose
riskmanagement on the basis of hazard alone (i.e., regulation
based solely on endocrine-disrupting properties) (Endocrine
Society 2009, 2015). Regulation by hazard has been
championed for the following reasons:Intethe occasional occurrence of nonmonotonic dose–
concentration responses, the possible absence of thresholds of effects in some
instances, concerns for possible insensitivity of current toxicological
and ecotoxicological tests to detect certain types of
endocrine system perturbation, and the possibility that short-term exposures to EDSmay lead
to long-term (i.e., latent) consequences not addressed
during testing.It has been suggested that these factors prevent the
confident prediction of no-effect doses or concentrations (ED
EAG 2013; EFSA 2013), although this point is controversial.
A key question is “How are regulators and policy makers to
decidewhether to select a hazard or a risk-based approach for a
given EDS under review?” Some (inter)governmental guidance
already is available on evaluation of the (eco)toxicological
properties of potential endocrine disruptors (e.g., DKEPA2011;
USEPA 2011a; OECD 2012c) but, to date, it has been uncleargr Environ Assess Manag 2017:267–279 DOI: 10.1002how or whether this information can be used to derive
acceptable environmental exposures, that is, assessment of
risk. There is a clear need for objective advice, based on the
current level of scientific understanding, to allow regulators and
policymakers tomakecomprehensive, science-baseddecisions.
The paper was a product of the SETACPellstonWorkshop
1
“Environmental Hazard and Risk Assessment Approaches for
Endocrine-Active Substances (EHRA),” held 31 January to 5
February 2016 in Pensacola, Florida, USA, with the participa-
tion of 48 invited international experts from 9 countries, as
authors of the present paper. Backgrounds of the participants
were varied, with 27% of the participants from government,
27% from academia, 21% from industry, and 25% attending
as independent consultants. In addition to the present paper,
4 companion papers, based on insights gained from case
studies of specific EAS, are being published simultaneously
as output of this workshop.
With expert contributions from industry, government, and
academia, the SETAC Pellston Workshop developed consen-
sus-based advice on scientifically defensible approaches for
the assessment of EDS. The present paper outlines the
circumstances in which risk assessment of an environmental
EDS may be acceptable and those in which a hazard-only
approach is warranted. The paper is primarily aimed at
scientists and hazard or risk assessors responsible for the
development and regulation of chemicals, whether in industry,
government, or academia, and it provides guidance on
scientifically justifiable assessment procedures. It also high-
lights areas of scientific uncertainty and presents recommen-
dations for research to address these issues. Regulators and
others are invited to takenoteof thepaper’s recommendations
when drafting their own guidance for evaluating EAS and EDS.
METHODS
To facilitate the identification of key factors when evaluat-
ing EAS and EDS, 6 substances for case studies were chosen
as representative of a range of endocrine modes of action:/iea17a-ethinylestradiol (EE2),
 perchlorate,
 propiconazole,
 17b-trenbolone,
 tributyltin (TBT), and
 vinclozolin.(Supplemental Data S1 through S6 present the case study
summaries and literature selected; S7 gives the methods
used to perform the case studies).
The substances for the case studies were selected so that
they covered a range of endocrine pathways or actions of
concern (estrogen agonism, thyroid antagonism, steroido-
genesis inhibition, androgen agonism, retinoid receptor
modulation, and androgen antagonism, respectively). In all
cases, these chemicals were considered to be data rich in
relevant information for 1 or more ecologically relevant taxa
at multiple levels of biological organization from theC 2017 The Authorsm.1885
270 Integr Environ Assess Manag 13, 2017—P Matthiessen et al.biochemical to the whole organism and, sometimes, the
population. However, it is important to note that the case
studies are not comprehensive safety evaluations but, rather,
provided the foundations for examining the key issues and
procedures discussed in this paper.
The case study groups conducted hazard and risk assess-
mentsmaking use of published guidance. The guidance used
and full details of the case study assessments can be found in
the Supplemental Data S1. Each group followed a similar
process but with differences according to the information
available. The general work flow for the case studies is
summarized in Supplemental Data Figure S7-1.
All groups conducted searches of the published literature,
openly accessible regulatory datasets, and other sources
such as test guideline validation studies and high throughput
in-vitro assays (ToxCastTM; USEPA 2016a). Literature studies
were first assessed for relevance, and then evaluated for
reliability using the Toxicological Data Reliability Assessment
Tool (ToxRTool) (Schneider et al. 2009) and/or Klimisch
criteria (Klimisch et al.1997).
A potential shortcoming identified prior to the workshop
was the lack of reliable assessment data for histopathology
endpoints and an inability to access studies submitted in
confidence to regulatory agencies. Evaluation of histopa-
thology data requires specialized expertise, and despite the
frequent occurrence and integral role of this evaluation
among the reviewed studies, it was recognized that this
subject is not addressed specifically within either the Klimisch
or ToxRTool frameworks. Consequently, histopathology data
were assessed for reliability in a parallel exercise, the results
of which were incorporated into the case study evaluations.
Studies were then assembled in a framework in order to
collate data on effects relevant for assessing the endocrine
axes. In most cases (vinclozolin, trenbolone, TBT, EE2, and
perchlorate), the levels of assessment established by the
OECD Framework (CF) for the Testing and Assessment of
Endocrine Disruptors (OECD 2012b) were used as a guide.
Each group examined the available data to determine
whether their substance exhibited the potential for interac-
tion with a specific pathway in vitro or in vivo and exhibited
adverse effects potentially mediated by that pathway.
Adverse effects observed in higher-tier tests were queried
to determine whether they were corroborated by lower-tier
tests, and whether they could be concluded to be a
consequence of endocrine activity.
The groups usedweight-of-evidence (WoE) assessments of
various types to determine interaction with endocrine
systems and potential associations with adverse effects.
The propiconazole and perchlorate groups used a system
similar to that of the US Environmental Protection Agency
(USEPA 2011a) in which the responses (positive, negative, or
no change) of each relevant endpoint were tabulated and
organized according to interaction with endocrine axes. The
propiconazole group explicitly used the hypothesis-testing
methods recommended by Becker et al. (2015). The TBT,
trenbolone, and EE2 groups used adverse outcome path-
ways (AOP) (Ankley et al. 2010) to structure theWoE process.Integr Environ Assess Manag 2017:267–279 wileyonlinelibrary.cAdverse outcome pathways are designed to depict causal
linkages between a specific endocrine activity or molecular
initiating event (MIE) such as receptor activation or inhibition,
and adverse apical outcomes (e.g., reduced fecundity,
altered sex ratios). Finally, following the hazard characteriza-
tion, exposure estimates were generally incorporated in
order to assess possible differences in hazard- versus risk-
based decisions.
The results of the case studies then provided many
examples of crosscutting, data availability, and interpretation
issues, typically common to several substances, which may
have an impact on decisionmaking. These are shown in detail
in the case study Supplemental Data and have been used to
design the suggested strategy (see Section Proposed
Decision-Making Strategy to Support Endocrine Disruptor
Ecotoxicological Hazard VERSUS Risk Assessment) for
deciding on whether a sound risk assessment of a particular
EDS can be undertaken.
CROSSCUTTING ISSUES RELEVANT TO THE
EVALUATION OF HAZARDS AND RISKS OF EAS
AND EDS
As case study groups conducted their analyses of the 6
EAS, a series of crosscutting issues with relevance to the
hazard and risk assessment of EAS and EDS were identified.
By “crosscutting issues,” we mean problems of evaluation
that were common to several of the case studies. Some of
these are discussed with respect to their application in an
improved ecotoxicological hazard and risk assessment. A
number of issues were also identified that play a role in
determining whether an EDS can confidently be subjected to
ecotoxicological risk assessment, or whether regulation by
hazard is the most appropriate option. Finally, issues were
identified that aid in distinguishing between endocrine-
versus nonendocrine-specific responses. These crosscutting
issues are broadly outlined below and discussed in detail in
the associated companion papers (Coady et al. this issue;
Marty et al. this issue; Mihaich et al. this issue; Parrott et al.
this issue).
Challenges in assigning endocrine-specific modes of action
Amajor challenge in the assessment of EAS is understand-
ing the primary mechanism of action, in the context of
perturbation of an endocrine target of concern (i.e., the MIE).
Whereas identifying the mechanistic basis for how a
substance acts is not necessarily a requirement for perform-
ing a traditional risk assessment, the ability to distinguish
between endocrine and nonendocrine-mediated responses
is necessary when specific regulatory outcomes are tied to
assigning causality between perturbation of a specific
pathway and an adverse effect. Thus, there is a need for
careful study design and data interpretation to distinguish
between endocrine versus nonendocrine-specific responses.
The WHO IPCS definition of an endocrine disruptor is broad,
and a very precautionary interpretation might capture many
mechanisms that, in general, would not specifically be
considered to be endocrine disruption (Dang 2016; WheelerC 2017 The Authorsom/journal/ieam
Ecotoxicological Evaluation of Endocrine-Active Substances—Integr Environ Assess Manag 13, 2017 271and Coady 2016). For instance, hepatotoxicity can
potentially cause decreased levels of vitellogenin in female
fish (Miller et al. 1999), leading to reproductive failure, an
effect analogous to some chemical effects on estrogen,
androgen, and thyroid (EAT) pathways.
The likelihood of indirect effects is increased in (eco)
toxicological studies requiring the use of maximum
tolerated dose or concentration test levels, which must
produce some adverse effects (Wheeler et al. 2013;
Witorsch 2016). The OECD CF levels 4 and 5, which cover
aquatic tests with apical endpoints, recommend a maxi-
mum test concentration of 1/10th of the acute LC50, or
range-finding studies to avoid overt toxicity (see OECD TG
234, 240, 241; in OECD 2017; Wheeler et al. 2013), which
decrease the likelihood of indirect effects (i.e., apparent
endocrine responses caused by interactions mediated via
nonendocrine mechanisms). The misidentification of endo-
crine disruption as a direct cause of effects where it is
actually an indirect cause has serious consequences in
terms of triggering animal and resource-intensive testing
and potentially severe regulatory outcomes. A WoE
approach, similar to that used by Becker et al. (2015), can
be used to explore endocrine-specific modes of action. This
approach is based on biological plausibility, empirical
support, and essentiality of key events in an AOP. It has
been used to evaluate diagnostic (endocrine-specific and
nonendocrine mechanisms) and apical endpoints to inves-
tigate whether an endocrine mechanism can be conclu-
sively assigned to the effects observed for a given
substance. The use of an AOP approach to assemble the
lines of evidence that lead to an adverse effect helps to put
into context the various mechanisms that may be responsi-
ble. This approach was used to examine 3 of the case study
substances, EE2, propiconazole, and 17b-trenbolone (Sup-
plemental Data S1, S3, and S5; Mihaich et al. this issue).
Uncertainties in biological responses that influence hazard
and risk approaches to the regulation of EAS and EDS
Endocrine-disrupting substances may have certain biolog-
ical effects, including delayed or multigenerational impacts
(i.e., latent effects), or they may display nonmonotonic dose–
response relationships (NMDRs) experimentally that require
careful consideration when determining ecotoxicological
hazard or risk. This topic is addressed in detail in a companion
paper (Parrott et al. this issue). For example, EDS can have
specific and profound effects when exposure occurs during
sensitive windows of the life cycle. This exposure creates the
potential for delayed responses where the actual adverse
effect is manifest at life stages different from those during
which exposure occurred. An example is sex reversal in fish, if
exposure to certain EDS occurs over the period of sexual
differentiation (e.g., McAllister and Kime 2003), where the
actual adverse population-relevant effect is not manifested
until the fish reach sexual maturity with consequent impaired
reproductive capacities (Nash et al. 2004). This underscores
the need for testing during appropriate (sensitive) life stages
and, when necessary, full life cycle designs that are intendedIntegr Environ Assess Manag 2017:267–279 DOI: 10.1002to capture adverse effects where and whenever they occur.
The potential for effects to be manifest in subsequent
generations (multigenerational effects) also has been raised
as a potential issue in the derivation of appropriate endpoints
for EDS. Concern for this potential is reflected in the design of
the new higher-tier tests to assess EAS developed under the
auspices of the OECD and USEPA, which are moving toward
extended 1-generation designs for fish (OECD TG 240) and
mammals (OECD TG 443 in OECD 2017).
It has been hypothesized that the occurrence of NMDRs is
also an uncertainty for reliable risk assessment of EDS.
Substantial data reviews are underway to inform on their
occurrence and relevance (e.g., EFSA external report http://
www.efsa.europa.eu/en/supporting/pub/1027e). However,
at this time evidence indicates that NMDRs may be most
prevalent in in-vitro tests (e.g., due to cell toxicity; Berckmans
et al. 2007; Dang 2009; Lagarde et al. 2015) and in in-vivo
mechanistic studies (e.g., due to feedback-mediated com-
pensatory responses [Ankley and Villeneuve 2015]), and not
generally translated to adverse apical endpoints thatwouldbe
employed in risk assessment, although such examples have
been documented ( €Orn et al. 2003). Others have provided
guidance for characterizing NMDRs (Lagarde et al. 2015), and
a flowchart of how to evaluate NMDRs in the context of
endocrinehazardand risk assessmentprocedures ispresented
in a companion paper (Parrott et al. this issue).
Overall we can conclude that, if careful consideration of
delayed, multigenerational (i.e., latent), and NMDR effects is
made, it is feasible to assess ecotoxicological endocrine
hazards and derive robust endpoints for risk assessment
procedures ensuring a high level of environmental protec-
tion. It should, however, be noted that these types of data are
currently available for relatively few chemicals.
Improved methods for the assessment of EAS and EDS
To assess either hazards or risks of possible EAS or EDS
requires robust, validated test methods that detect pertur-
bation of endocrine pathways of concern, provide insights as
to potential adverse apical effects, and offer information on
the concentrations at which these effects occur. Further, the
assays should be capable of generating necessary informa-
tion in a timely and cost-effective manner that minimizes, as
much as possible, use of test animals. A number of in-vivo test
systems have been developed and are available for the
assessment of EAS or EDS in different regulatory settings.
However, there are several inherent limitations to the
collection and interpretation of data from these assays,
which are addressed in detail in a companion paper (Coady
et al. this issue).
One issue of significant concern to current EAS screening
and testing programs involves resources in terms of cost,
time, personnel, and animal use. This issue is especially
problematic when considering the number of chemicals that
some regulatory authorities need to assess; for example, the
Endocrine Disruptor Screening Program (EDSP) in the United
States has been charged with considering potential endo-
crine-mediated effects of around 10000 chemicals, a taskC 2017 The Authors/ieam.1885
272 Integr Environ Assess Manag 13, 2017—P Matthiessen et al.that clearly cannot be achieved solely with in-vivo tests
(USEPA 2011b). One way to address this challenge is to
prioritize chemicals for possible in-vivo testing using in-vitro
high-throughput (HTP) assays focused on a suite of MIEs of
concern. An example of how this type of approach could be
used was recently described for estrogen receptor activation
in mammals (USEPA 2014). Consideration of additional
endocrine MIEs of concern, and expansion of the prioritiza-
tion strategy to consider non-mammalian species, based on
concepts of pathway conservation, is a technically reasonable
prospect (Ankley et al. 2016; Coady et al. this issue).
One challenge associated with the design and conduct of
in-vivo EAS screening and testing is the selection of
appropriate (i.e., sensitive) species, endpoints, and life
stages. A component of this involves the experience gained
from existing tests to determine, for example, particular
assays that may be exceptionally sensitive to perturbation of
a given MIE of concern (e.g., Ankley and Gray 2013). In
addition, though, there is promise for the strategic use of HTP
data and/or early screening-level information (based, e.g., on
computationalmodels) to help guide the selection of existing
assays that are most likely to be sensitive to a given EAS
modality. For example, Coady et al. (this issue) show howHTP
data for 17ß-trenbolone would help subsequent in-vivo
testing to focus on assays that measure vertebrate reproduc-
tion and sexual development.
Additional challenges for EAS in-vivo screening and testing
involve guidance for, and optimization of, a number of
pragmatic issues inherent to the conduct of in-vivo (and
occasionally in-vitro) assays, such as concentration setting,
statistical power and sensitivity, delivery and analytical
measurement of test substances, availability of technical
expertise, and study interpretation, including the linking of
mechanistic and apical effects. Coady et al. (this issue) address
these challenges and offer several potential solutions, where
applicable. Finally, a number of recommendations are
provided for longer-term research efforts to address areas
of uncertainty, including the need for a better understanding
of the endocrine system of invertebrates, followed by the
development of assays in potentially sensitive species
(including invertebrates) for which (endocrine) test methods
currently do not exist. One area of uncertainty is the role of key
endocrine pathways in addition to EAT signaling (e.g.,
glucocorticoid, progesterone, and retinoid pathways) and
an understanding of the relationship of perturbations in these
pathways to population-relevant effects.
Population-relevant endpoints in the evaluation of EAS for
ecological hazard and risk assessment
Many endpoints (from subcellular through intact organism
individual-level changes) havebeen used to evaluate endocrine
mechanisms and effects in different taxa, but the link between
these endpoints andpopulation-level effects is often undefined
(Kramer et al. 2011). This lack of definition is a source of major
uncertainty for both hazard and risk assessment. The compan-
ionpaperbyMarty et al. (this issue) useddata from theEAScase
studies (Supplemental Data S1–S6) to evaluate the populationIntegr Environ Assess Manag 2017:267–279 wileyonlinelibrary.crelevance of collected study endpoint data in the context of
ecotoxicological hazard and risk assessment for various taxa
(invertebrates, fish, amphibians, birds, and mammals).
Population-relevant endpoints generally include effects at
the individual level on fitness (i.e., behavior, growth and
development, reproduction, and survival). Examples of such
effects are described by Marty et al. (this issue). The
development of new methodologies, including AOPs and
population modeling, will foster a more complete under-
standing of the relationship between endocrine perturba-
tions at lower levels of biological organization and adverse
population-level effects. These methods may allow quantita-
tive inferences about population-relevant effects from
physiological changes (e.g., dynamic energy budgets: Martin
et al. 2012), and predictive systemmodels also show promise
(Forbes and Calow 2012; Watanabe et al. 2016). However,
until an established linkage between these endpoints and
subsequent population changes are evident, such endpoints
should not be used to drive the risk assessment of EDS.Marty
et al. (this issue) have, in addition, examined recovery in
endpoint responses, which may be particularly important
when evaluating effects of EDS on populations.
PROPOSED DECISION-MAKING STRATEGY TO
SUPPORT ENDOCRINE DISRUPTOR
ECOTOXICOLOGICAL HAZARD VERSUS RISK
ASSESSMENT
Methods for identifying EAS and EDS have been available
for some time (see Supplemental Data). The main area where
guidance is lacking concerns the decision to subject these
substances to ecotoxicological risk as opposed to hazard
assessment. This problem is particularly relevant for data-
poor substances for which few species or endpoints will have
been studied. A number of potential questions that address
the reliability of ecotoxicological risk assessment have been
identified:om/Is exposure of wildlife probable?
 Is prediction (or measurement) of exposure reliable?
 Have the most appropriate taxa been tested (with
relevant endpoints)? Have sensitive life stages, or the entire life cycle, been
tested (again with relevant endpoints)? Have delayed and multigenerational (i.e., latent) effects
been considered? Do NMDRs or other unusual temporal patterns of toxicity
affect the ability to predict reliable no-adverse-effect
levels? Does a threshold for adverse endocrine-mediated effects
exist?Each of these issues has the potential to make an
ecotoxicological risk assessment uncertain. It might be
argued that most of the uncertainties could be addressed
through the use of additional assessment factors (AF),
otherwise known as “uncertainty factors.” In general, their
usemay be acceptable but should be justified by reference toC 2017 The Authorsjournal/ieam
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also possible that uncertainty can be reduced by using tools
such as ToxCast (USEPA 2016a) to identify potential
endocrine activities, by reading across from data derived
from substances that share the same AOP (e.g., Becker et al.
2015), or by obtaining additional test data.Figure 1. A suggested decision-making strategy for assessing whether a scientifi
Stop, consider whether a risk assessment of non-EDS hazards is required. This of
disrupting substance.
Integr Environ Assess Manag 2017:267–279 DOI: 10.1002A possible strategy for addressing some of the questions
listed above is shown in Figure 1. It should be noted that the
flow chart is intended for use in situations where a substance
has already been clearly identified as an EDS, and therefore
decisions about whether or not to initiate ecotoxicological
risk assessment need to be made. The issues underpinningcally sound risk assessment of an EDS can be reliably performed. On exiting at
course applies only if wildlife exposure is expected to occur. EDS¼ endocrine-
C 2017 The Authors/ieam.1885
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entitled Cross-Cutting Issues Relevant to the Evaluation of
Hazards and Risks of EAS/EDS, and at length in the
accompanying papers (Coady et al. this issue; Marty et al.
this issue; Mihaich et al. this issue; Parrott et al. this issue).
The first substantive question (Figure 1, Question 1) is
whether exposure to wildlife will occur. Under certain
situations, this question can be excluded if exposure is limited
to closed systems such as greenhouses, with no or extremely
limited routes to thewider environment. In such cases, neither
an ecotoxicological hazard nor risk assessment is required.
The second question (Figure 1, Question 2) is whether
exposure measurement or prediction can be conducted
reliably across compartments within ecosystems. There may
be many reasons for difficulties with this question, but
perhaps the most important concerns very potent substan-
ces, such as EE2, that may be active below their limit of
quantitation in water or food items. Difficulties also arise for
substances with some similarities to the POPs, such as methyl
Hg, whose persistence, long-range transport, and bioaccu-
mulation potential lead to their global distribution and
biomagnification in food chains at sites remote from their
point of use. Prediction of exposure may also be difficult or
impossible for some chemicals that enter the environment by
poorly understood routes or in unknown quantities. Guid-
ance to suitable exposure prediction methodologies can be
found in the European Chemicals Agency (ECHA 2016a,
2016b), FOCUS (2016), JRC (2016), and USEPA (2016b).
Inability to measure or predict ambient concentrations of an
EDS (or indeed any other substance) precludes the use of
toxicity data in risk assessment, and for purposes of
regulation it would then be assumed that exposure to levels
sufficient to produce adverse effects could occur.
If exposure measurement or prediction is deemed
sufficiently reliable, the next question (Figure 1, Question
3) is whether the responses of a relevant taxon, life stage, and
endpoints have been adequately assessed. Even quite
closely related species can vary considerably in their
sensitivity to EDS. For example, in a whole-lake experiment
with EE2, some short-lived fish species failed to reproduce,
whereas others were apparently unaffected (see Supplemen-
tal Data S1 EE2; Palace et al. 2009). Similar issues arise for
other EDS and species; for example, 17b-trenbolone causes
androgenic effects in a variety of species, but with greatly
varying potency (see Supplemental Data S5 Trenbolone).
This issue underscores the importance of tiered and
intelligent testing strategies that identify the relevant
receptors and perform the most extensive testing and
assessments of those. This uncertainty can be addressed
by testing additional species that share responsiveness to a
common signaling pathway, read-across from related chem-
icals, and knowledge about the degree of cross-species
conservation of relevant endocrine MIEs and AOPs, to make
judgments about whether sensitive species are likely to have
been tested (Coady et al. this issue).
There can also be a wide range of sensitivity of different life
stages within a species, with the window of greatestIntegr Environ Assess Manag 2017:267–279 wileyonlinelibrary.csensitivity to EAT substances often occurring during early
sexual development (see EE2 and trenbolone SI). For this
reason, datasets that lack information derived from exposure
of developing organisms should be treated with caution.
If the sensitivity of test organisms has been adequately
addressed, it becomes necessary to deal with the potential
for delayed andmultigenerational effects (Figure 1, Question
4). These effects may be of particular concern if sensitive
developmental stages have been exposed but not followed
through tomaturity or into the next generation. In some cases
where sufficient information concerning perturbation of a
given endocrine pathway is known, study of delayed effects
may not be necessary if the appropriate sensitive life-stage
has been covered (in line with intelligent testing strategies). A
good example of delayed effects concerns alterations of
phenotypic sex ratios in juvenile and adult fish exposed as fry
to EDS such as estrogens and androgens (see case studies
and tables for Supplemental Data S1 for EE2 and S5 for
trenbolone). Although data on multigenerational effects are
still scarce (and exceptions to the following statements do
exist, e.g., Chen et al. [2015]), information from the case
studies suggests that fish from the second (F2) generation
only rarely show greater sensitivity than the first (F1)
generation during continuous exposure (Supplemental
Data S1 and S3). Indeed, this is the basis of extended 1-
generation test designs implemented for higher-tier testing
of EAS (OECD TGs 240 and 443 – see OECD 2017). If there is
sufficient information to suggest delayed or multigenera-
tional effects, additional testing is likely needed if suitable
methods such as life cycle tests are available.
When it has been concluded that delayed toxicity and
possible multigenerational effects have been adequately
accounted for, it becomes important to consider whether the
substance possesses properties that might impair the ability
to predict no-effect concentrations or doses (Figure 1,
Question 5). In other words, has the dose– or concentra-
tion–response relationship been adequately described?
Nonmonotonic dose–response relationships can occur in
both in-vitro and, for some endpoints, short-term in-vivo
studies with EDS. However, such response curves may not be
broadly predictive of similar effects in long-term in-vivo
studies with apical endpoints (see case studies and tables for
Supplemental Data S4 for TBT, S1 for EE2, and S5 for
trenbolone; USEPA 2013). A structured approach to tackling
the NMDR issue for both mechanistic and apical endpoints is
proposed in Lagarde et al. (2015) and Parrott et al. (this issue).
The 2 NMDR flowcharts in Parrott et al. (this issue) consider
aspects of reproducibility and biological plausibility, and
whether a threshold can be determined. In summary, if an
NMDR is observed and confirmed in an apical test with
population relevance, further testing at lower concentrations
and appropriate exposure times should be considered in
order to establish a defensible no-effect concentration
(NOEC) or ECx.
Regulation of EDS on the basis of hazard alone may be
partly driven by a perception that these substances do not
have a toxic threshold (Parrott et al. this issue). However, it isC 2017 The Authorsom/journal/ieam
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EDSdo not exist, and attempts to do sowould involve the use
of impractical, not to mention unreasonable, numbers of test
organisms. Most significantly, a viable physiological basis for
such absent thresholds has not been clearly identified.
Furthermore, there is no evidence that such effects apply to
populations of organisms, the defined protection goal of
most global policies and regulations (with the exception of
those aimed at protecting rare or endangered species).
Thresholds of toxicity were present for all the case study
substances (see Supplemental Data), and theoretical consid-
erations suggest that endocrine systems could not function if
such thresholds were absent (Borgert et al. 2013). However,
as indicated in the section entitled Cross-Cutting Issues
Relevant for the Evaluation of Hazards and Risks of EAS/EDS,
the absence of thresholds may be truly applicable only to
population-level effects because a small proportion of
individuals may show background endocrine effects unre-
lated to EDS exposure. Probabilistic approaches to the
identification of true thresholds show some promise (Hanson
and Solomon 2002).
If the concerns articulated in this section are considered to
have been satisfactorily addressed, then it is technically
defensible to conduct an ecotoxicological risk assessment
using specific exposure and dose–response data. Otherwise,
the precautionary approach of deriving PNECs using AFs
could be considered if further data generation cannot resolve
outstanding issues. In the absence of adequate data or
modeling results, assessment on the basis of hazard is
scientifically justified until such time as relevant new
information is available. It is important to bear in mind that
although current internationally standardized tests are not
diagnostic for non-EAT endocrine modalities, available
methods such as life cycle tests probably detect the majority
of apical effects regardless of whether endocrine or non-
endocrine mechanisms are involved, and development of
new test methods (e.g., OECD 2012a) will further expand our
level of confidence that serious effects have not beenmissed.
KNOWLEDGE GAPS IN ENDOCRINE SCREENING
AND TESTING
Several areas where further research is needed were
identified at the workshop, and the main points are
highlighted here; for more detail, see the companion papers
in this series (Coady et al. this issue; Marty et al. this issue;
Mihaich et al. this issue; Parrott et al. this issue). Many of these
areas involve the need for fundamental biological research,
but there is also a need for the development of new testing
methods.
Consideration of additional endocrine pathways
There is a clear need to consider a wider range of
endocrine pathways of concern; there are at least 48 different
soluble nuclear receptors that bind with ligands to produce
their actions, of which many are currently ignored. There also
are more hormones than are analyzed at present. Conse-
quently there is a need to develop a wider understanding ofIntegr Environ Assess Manag 2017:267–279 DOI: 10.1002the ways in which endocrine pathways can be perturbed, and
to produce implementable tools for their study.
Test methods for under-represented taxa and pathways
There is a need for invertebrate tests with mechanistic
endpoints in the context of chemical perturbations (MIEs,
AOPs). For example, it would be desirable to develop a
screening assay that evaluates the retinoid X receptor (RXR)
pathway, which is important in mollusks as well as vertebrates
(e.g., fish). However, most developments of this type will
depend on improvements in our understanding of inverte-
brate endocrinology, particularly for nonarthropods. More
screening assays are also needed for vertebrates, especially
for some birds and reptiles with which apical studies cannot
be readily conducted for logistical reasons.
Secondly, there are methodological gaps that affect the
current EDS testing paradigm of progression from screening
to apical testing. For example, there are standardized apical
tests for mollusks, mysids, and birds, but screening tests are
needed for these taxa so that triggers of such apical tests can
be defined. These issues will need to be explored as
additional higher-tier data are generated.
Behavioral endpoints
Endocrine-disrupting substances are known to alter behav-
ior by affecting the central nervous system (CNS) via
endocrine-mediated mechanisms during intrauterine or neo-
natal life, puberty, or adulthood (e.g., Gray and Ostby 1998).
Risk topopulations from inappropriateor ill-timedcourtshipor
parental behavior (e.g., migration, nesting, lactation) is as
significant as the repercussions from disrupted ovulation or
spermatogenesis. Consequently, there is a need to identify
such additional, potentially sensitive behavioral endpoints in
the context of endocrine perturbation, specifically for birds in
which suchendpointsarenotsufficiently included in regulatory
testing and to link these, on the one hand to MIEs and on the
other hand to population-level effects.
Determining adversity of effects
There is aneed formorepopulation-levelpredictivework for
a representative rangeof organisms, inparticular todetermine1)/iethe extent to which delays in development or reduction in
reproductive output constitute adverse effects at the
individual and population levels;2) whether the lossof ageclasses asa resultof affectedgrowth
has an impact at the community and ecosystem levels;3) the extent to which adaptation and recovery affect
population-level impacts; and4) the quantitative relationship among initiating events, key
events, and adverse population-level effects.
Species sensitivity and sensitive life stages or windows of
exposure
More information is needed to ascertain how sensitivity to
EDS varies with developmental stage. In addition, we need toC 2017 The Authorsam.1885
Table 1. Glossary of terms and acronyms used in the present paper and in the accompanying papers
Term or
acronym Definitiona
Adverse effect Change in the morphology, physiology, growth, development, reproduction, or life span of an organism, system, or
(sub)population that results in an impairment of functional capacity, an impairment of the capacity to compensate
for additional stress, or an increase in susceptibility to other influences.
AOP Adverse outcome pathway
AF Assessment factor
CNS Central nervous system
EAS Endocrine-active substance. A substance that can interact with an endocrine system to cause responses that may or
may not give rise to adverse effects.
EAT Estrogen, androgen, and thyroid pathways
ECx Effect concentration x. A toxicant concentration causing effects in x% of a test population.
EDS Endocrine-disrupting substance. An exogenous substance or mixture that alters functions of the endocrine system
and consequently causes adverse health effects in an intact organism, or its progeny, or (sub)populations (WHO/
IPCS 2002).
Hazard Inherent property of an agent or situation having the potential to cause adverse effects when an organism, system, or
(sub)population is exposed to that agent.
Hazard
assessment
A process designed to determine the possible adverse effects of an agent or situation to which an organism, system,
or (sub)population could be exposed.
HTP assays High-throughput assays
MIE Molecular initiating event
NMDR
relationships
Nonmonotonic dose–response relationships
NOEC No-observed-effect concentration
PBT Persistent, bioaccumulative, and toxic substances
PNEC Predicted no-effect concentration
POPs Persistent organic pollutants
Risk The probability of an adverse effect in an organism, system, or (sub)population caused under specified circumstances
by exposure to an agent.
Risk assessment A process intended to calculate or estimate the risk to a given target organism, system, or (sub)population, including
the identification of attendant uncertainties, following exposure to a particular agent, taking into account the
inherent characteristics of the agent of concern as well as the characteristics of the specific target system and
exposure.
Threshold Dose or exposure concentration of an agent below which a stated effect is not observed or expected to occur.
WoE Weight of evidence
aSome definitions adapted from IPCS (2004).
276 Integr Environ Assess Manag 13, 2017—P Matthiessen et al.determine whether short-lived species are more likely to be
impacted by EDS, or whether it is simply easier to identify
population-level effects within their shorter experimental
timeframe (e.g., Palace et al. 2009).
Predicting no-effect concentrations or toxic thresholds
Probabilistic methods for prediction of true thresholds
have been proposed (Hanson and Solomon 2002). There is
no reason to expect that these types ofmethods could not be
used for EAS and EDS, but more research in this field is
required, particularly on the mechanistic basis of issues such
as NMDRs, etc.Integr Environ Assess Manag 2017:267–279 wileyonlinelibrary.cCONCLUSIONS AND RECOMMENDATIONS
As summarized herein, and in the accompanying papers,
substantial guidance already is available on how to consider
the hazardous properties of an EAS and support a decision on
whether it is an EDS, using WoE approaches. However, the
present paper also identifies additional issues that should be
considered in hazard characterization and provides guidance
on how they can be addressed.
Key questions that should be asked before a risk
assessment is attempted include these:om/Is exposure of wildlife probable?C 2017 The Authorsjournal/ieam
Ecotoxicological Evaluation of Endocrine-Active Substances—Integr Environ Assess Manag 13, 2017 277InteIs prediction (or measurement) of exposure reliable?
 Have the most appropriate taxa and species been tested
(with relevant endpoints)? Have sensitive life stages, or the entire life cycle, been
tested (again with relevant endpoints)? Have delayed and multigenerational effects been
considered? Can reliable no-adverse-effect levels be predicted,
despite the possible presence of NMDRs or other unusual
temporal patterns of toxicity? Does a threshold for adverse endocrine effects exist?The primary conclusion of the present paper, and of the
SETAC Pellston Workshop on which it is based, is that if
responses to all of these questions are positive, it is
scientifically defensible to proceed with a standard risk
assessment.
If the response to any of these questions is negative (except
in those specific cases identified) or equivocal, there may be
an opportunity to address the uncertainty by further
modeling or testing before it is considered scientifically
sound to proceed to ecotoxicological risk assessment.
However, if suitable test or modeling methods are unavail-
able, the only alternativemay be to regulate the substance on
the basis of hazard alone, at least until such time as relevant
additional data become available.
GLOSSARY AND DEFINITIONS
Meanings of terms might not always be the same in
different regulatory jurisdictions or scientific disciplines.
Table 1 therefore provides meanings of acronyms and terms
as used in this and the accompanying papers.
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Heindel JJ, Jobling S, Kidd KA, Zoeller RT, editors. Geneva (CH): UNEP and
WHO. 289 p.
Witorsch RJ. 2016. Effects of elevated glucocorticoids on reproduction and
development: Relevance to endocrine disruptor screening. Crit Rev
Toxicol 46:420–436.
Zoeller RT, Bergman A, Becher G, Bjerregaard P, Bornman R, Brandt I, Iguchi T,
Jobling S, Kidd KA, Kortenkamp A, et al. 2015. A path forward in the debate
over health impacts of endocrine disrupting chemicals.EnvironHealth 14:118.
Zoeller RT, Brown TR, Doan LL, Gore AC, Skakkebaek NE, Soto AM, Woodruff
TJ, Vom Saal FS. 2012. Endocrine-disrupting chemicals and public health
protection: A statement of principles from The Endocrine Society.
Endocrinol 153:4097–4110.C 2017 The Authors/ieam.1885
